Clinical Scorecard: Assessment of Serum TWEAK Levels and Treatment Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Comparative Study of Adalimumab versus Methotrexate

At a Glance

Key Highlights

• TWEAK is implicated in both cutaneous and joint manifestations of psoriatic disease but its modulation by therapies is not well studied.
• Adalimumab (anti-TNF-α) is used for moderate-to-severe psoriasis; methotrexate is first-line DMARD for psoriatic arthritis in Egypt.
• Serum TWEAK levels measured by ELISA can serve as a biomarker for disease activity and treatment response over 24 weeks.

Guideline-Based Recommendations

Diagnosis

• Use PASI score to assess psoriasis severity based on lesion area and characteristics.
• Use DAPSA score to evaluate psoriatic arthritis activity combining joint counts, CRP, and patient-reported outcomes.
• Confirm PsA diagnosis using CASPAR criteria.

Management

• Treat moderate-to-severe psoriasis with adalimumab when unresponsive to topical or conventional systemic agents.
• Use methotrexate as first-line DMARD for psoriatic arthritis considering cost and accessibility.
• Monitor serum TWEAK levels as a potential biomarker for treatment response.

Monitoring & Follow-up

• Assess PASI and DAPSA scores at baseline and after 24 weeks of therapy.
• Measure serum TWEAK levels by ELISA at baseline and 24 weeks to monitor immune activation.
• Regular clinical and laboratory monitoring to exclude infections and organ dysfunction.

Risks

• Exclude patients with pregnancy, systemic infections, hepatic or renal insufficiency, hepatitis B/C, or tuberculosis before therapy.
• Monitor for adverse effects related to immunosuppression with biologics and methotrexate.

Patient & Prescribing Data

Adults with moderate-to-severe psoriasis or psoriatic arthritis naïve to systemic therapy

Adalimumab prescribed for psoriasis group; methotrexate prescribed for PsA group reflecting real-world standards and cost considerations.

Clinical Best Practices

• Obtain informed consent and ethical approval prior to patient enrollment.
• Use validated scoring systems (PASI, DAPSA) for objective disease activity assessment.
• Incorporate serum TWEAK measurement as a biomarker to correlate with clinical indices and treatment outcomes.
• Employ a systematic patient flow and transparent reporting to improve study clarity.
• Exclude patients with contraindications to immunosuppressive therapy to minimize risks.

References

• Psoriasis prevalence and impact
• Psoriatic arthritis overview
• TWEAK and Fn14 in inflammation
• Role of TWEAK in autoimmune disease
• Serum TWEAK measurement by ELISA
• Adalimumab in psoriasis treatment
• Methotrexate as first-line DMARD in PsA
• PASI scoring method
• DAPSA scoring in PsA